ErbB2/neu kinase modulates cellular p27Kip1 and cyclin D1 through multiple signaling pathways

Cancer Research

Volumn 61, Issue 17, 2001, Pages 6583-6591

  Lenferink, Anne E G ^a,e   Busse, Dagmar ^a,f   Flanagan, W Michael ^d,g   Yakes, F Michael ^a   Arteaga, Carlos L ^a,b,c  

^a Department of Medicine ^*  (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

^d GILEAD SCIENCES   (United States)

^e NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^f DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^g Sunesis Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GENE PRODUCT; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P27; UNCLASSIFIED DRUG;

ADENOVIRUS; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CELL CYCLE G1 PHASE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MITOSIS INHIBITION; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; STOICHIOMETRY; VIRUS INFECTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BREAST NEOPLASMS; CDC2-CDC28 KINASES; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIVISION; CYCLIN D1; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; ENZYME ACTIVATION; ENZYME INHIBITORS; G1 PHASE; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS; TYRPHOSTINS; UP-REGULATION;

EID: 0035419867     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Neuregulins and neuregulin receptors in neural development
2. Specificity within the EGF family/ErbB receptor family signaling network
3. Untangling the ErbB signalling network
4. Diversification of Neu differentiation factor and epidermal growth factor signalling by combinatorial receptor interactions
5. ErbB2 is a common auxiliary subunit of NDF and EGF receptors: Implications for breast cancer
6. ErbB2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
7. Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers
8. Single-chain antibody-mediated intracellular retention of ErbB2 impairs Neu differentiation factor and epidermal growth factor signaling
9. Kinase-deficient neu proteins suppress epidermal growth factor function and abolish cell transformation
10. The biology of ErbB2/neu/HER-2 and its role in cancer
11. Cell cycle checkpoints: Preventing an identity crisis
12. Cyclins and cancer. II. Cyclin D and CDK inhibitors come of age
13. CDK inhibitors: Positive and negative regulators of G1-phase progression
14. All aboard the cyclin train: Subcellular trafficking of cyclins and their CDK partners
15. Inhibitors of mammalian G1 cyclin-dependent kinases
16. Cloning of p27, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals
17. p27, a novel inhibitor of G1 cyclin/cdk protein kinase activity, is related to p21
18. Assembly of cyclin D-dependent kinase and titration of p27 regulated by mitogen-activated protein kinase kinase (MEK1)
19. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with ErbB2/neu
20. Identification of a novel inhibitor of mitogen-activated protein kinase kinase
21. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)
22. Blockade of the EGF receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGFα bigenic mice
23. A cytosine analog that confers enhanced potency to antisense oligonucleotides
24. An adenoviral vector encoding cyclin D1 induces cell cycle progression and apoptosis
25. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor in aggressive colorectal carcinomas
26. Glycogen synthase kinase-3β regulates cyclin DI proteolysis and subcellular localization
27. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas
28. Tyrosine kinase inhibition: An approach to drug development
29. Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site
30. Epidermal growth factor receptors in human breast carcinoma cells: A potential selective target for transforming growth factor α-Pseudomonas exotoxin 40 (TGFα-PE40) fusion protein
31. HER2 monoclonal antibodies
32. Cyclin E-CDK2 is a regulator of p27Kip1
33. Induction of p27 degradation and anchorage independence by Ras through the MAP kinase signaling pathway
34. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27
35. Ras pathways to cell cycle control and cell transformation
36. The p21 and p27 CDK "inhibitors" are essential activators of cyclin D-dependent kinases in murine fibroblasts
37. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
38. Reversible G1 arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27 independent of MAPK activity
39. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells
40. MAP kinase cascade is required for p27 downregulation and S phase entry in fibroblasts and epithelial cells
41. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway
42. Cyclin D1 is required for transformation by activated neu and is induced through and E2F-dependent signaling pathway
43. Cellular survival: A play in three Akts
44. New functional activities for the p21 family of CDK inhibitors
45. ErbB2 potentiates breast tumor proliferation through modulation of p27-Cdk2 complex formation: Receptor overexpression does not determine growth dependency
46. Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation
47. Kip1, increases its protein stability
48. Oncogenic signals of HER-2/neu in regulating the stability of the cyclin-dependent kinase inhibitor p27
49. Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4
50. Ligand-induced activation of A431 cell epidermal growth factor receptors occurs primarily by an autocrine pathway that acts upon receptors on the surface rather than intracellularly
51. The cellular response to neuregulins is governed by complex interactions of the ErbB receptor family